RE-BVS – Piemonte Repository

Sfoglia per AUTORE
LEDDA A
Collezione AOU Città della Salute di Torino

Items : 5

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. in Blood / Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.

2024
AOU Città della Salute di Torino

Paris L; Zambello R; Mancuso K; Gamberi B; Palmas AD; Gozzetti A; Cellini C; Ballanti S; Velluti C; Vincelli ID; Ronconi S; Pavone V; Grasso M; Ledda A; Oliva S; Corradini P; Morè S; Belotti A; Rota-Scalabrini D; Bertuglia G; D'Agostino M; Petrucci MT; Bruno B; Musto P; Gay F;

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6.

2022
AOU Alessandria
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Belotti A; Tacchetti P; Fazio F; Zambello R; Luppi M; Liberati AM; Palmieri S; Annibali O; Monaco F; Galieni P; Pisani F; Capra A; Gilestro M; Curci P; Pascarella A; Tosi P; De Sabbata G; Pietrantuono G; Gentile M; Ledda A; Paris L; Morè S; Corradini P; Rota-Scalabrini D; Oliva S; Bertamini L; et alii...

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. in Haematologica / Haematologica. 2020 Apr;105(4):1074-1080. doi: 10.3324/haematol.2019.220657. Epub 2019 Jun 27.

2020
AOU Città della Salute di Torino

Palumbo A; De Paoli L; Romano A; Zambello R; Falcone AP; Giuliani N; Paris L; Fraticelli V; Amico V; Musto P; Bernardini A; Cangiolosi C; Innao V; Oddolo D; Benevolo G; Spada S; Evangelista A; Patriarca F; Ledda A; Liberati AM; Offidani M; Mina R; Larocca A; Montefusco V; Hájek R; Boccadoro M; Bringhen S;

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. in Blood / Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4.

2016
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Palumbo A; Boccadoro M; Hajek R; Montefusco V; Guglielmelli T; Ledda A; Liberati AM; Ruggeri M; Zambello R; Maisnar V; Conticello C; Pulini S; Ciccone G; Bernardini A; Giuliani N; Musolino C; Gentili S; Pietrantuono G; Falcone AP; De Paoli L; Mina R; Patriarca F; Benevolo G; Offidani M; Bringhen S; Magarotto V;